Brad Bolon Joins Endpoint, Strengthening Pathology Expertise in Neurotoxicity and Translational Disease Models

August 15, 2025

An internationally recognized expert in comparative and toxicologic neuropathology, Dr. Brad Bolon brings over 30 years of experience in phenotypic analysis, disease model development, pathology-driven discovery, and nonclinical safety assessment across a wide range of therapeutic platforms.

Endpoint Preclinical is proud to welcome Brad Bolon, DVM, MS, PhD, DACVP, DABT, FATS, FIATP, FRCPath to our Expert Network. With a career that spans industry, academia, contract research, and private consulting, Brad is widely regarded as one of the foremost authorities in toxicologic neuropathology and comparative pathology. He has played pivotal roles in translational research programs advancing small molecules, biologics, cell and gene therapies, and medical devices, with a particular emphasis on interpreting neurotoxic effects in preclinical models. View Brad’s Profile

Brad’s consulting practice centers on the morphologic analysis of CNS and PNS tissues, providing focused support in study design, tissue sampling approaches, pathology data generation and interpretation, and manuscript development. He delivers detailed evaluations in rodents and nonrodent species alike, supporting discovery, efficacy, and safety programs. His microscopy-based assessments emphasize accuracy, reproducibility, and translational context, helping clients generate meaningful conclusions from complex tissue-based findings.

Brad has served as a study pathologist or peer reviewer on several thousand GLP and non-GLP studies, often in programs with high translational impact. He has contributed to the preclinical development of therapeutics such as Kineret™, Prolia™, Nplate™, and Zolgensma®, where clarity in communicating the nature and implications of neuropathology findings were critical to regulatory success.

“I consult because it gives me the opportunity to choose meaningful projects, ones where my skills directly support the development of innovative life-changing therapies for patients with severe diseases,” says Brad. “My aim is to help teams generate data that are not only scientifically rigorous, but also clear, actionable, and aligned with real-world regulatory expectations.”

As a mentor and educator, Brad has taught generations of scientists and technicians the principles of neural tissue handling, microscopic interpretation, and comparative pathology. He has held an academic appointment at The Ohio State University and served as a frequent lecturer, advisor, and committee member within leading pathology and toxicology societies. His contributions have been recognized with prestigious accolades, including the 2021 STP Outstanding Mentor Award and the 2025 STP Lifetime Achievement Award.

Brad’s schedule is carefully curated due to the volume and specialization of his ongoing work, and he typically engages on highly focused, remote-based projects that benefit from his diagnostic precision and scholarly perspective. His availability for pathology peer review and microscopic interpretation offers Endpoint clients access to one of the field’s most respected voices in neuropathology.

“Brad is a clear leader in his field, recognized for the depth and precision of his work, and we’re thrilled to have him join Endpoint. His expertise aligns perfectly with our mission to give clients access to the world’s best minds, exactly when they need them, so they can strengthen study design, make the right model and endpoint choices, and reduce unnecessary spend. Brad further enhances our already exceptional neuro offering, expanding on our existing surgical, data collection, analysis, and training capabilities through the single-point-of-contact model that defines Endpoint.” — Cole McLarty, CEO, Endpoint Preclinical

Please join us in welcoming Dr. Brad Bolon to Endpoint Preclinical. To explore how Brad’s expertise can support your pathology or neurotoxicity program, contact us.